Vancouver, British Columbia – August 27, 2024 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”) is pleased to announce it has entered into an intellectual property conveyance agreement (the “Agreement”) with Ludwig Enterprises Inc. (“LUDG”) and Dr. Marvin S. Hausman (“Hausman”), CEO of Ludwig, pursuant to which the Company shall assign to Ludwig all of its intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along with any and all data accumulated testing these assays (the “Property”).

Vancouver, British Columbia – January 03, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”) announces the appointment of Dr. Georg Hochwimmer to the Company’s Board of Directors, effective December 29, 2023.
 Dr. Hochwimmer is Chief Analyst at General Research, GmbH, a leading Munich-based securities research and analysis firm. Dr. Hochwimmer is a noted business consultant and academic...